Key highlights
- The license agreement was executed on February 3, 2026.
- The compounds are at the preclinical stage and target autoimmune diseases.
- This is the second license agreement between the companies, following one in June 2022.
Agreement Details
On February 3, 2026, Asahi Kasei Pharma and Alchemedicine signed an exclusive global license agreement. This deal grants Asahi Kasei Pharma worldwide rights to research, develop, manufacture, and commercialize novel lead compounds identified by Alchemedicine's HiSAP™ platform.
Preclinical Compounds
The compounds are currently at the preclinical stage and are expected to have therapeutic potential for multiple autoimmune diseases. Asahi Kasei Pharma will determine specific target indications as development progresses.
Partnership History
This agreement marks the second collaboration between the two companies, following an initial license agreement in June 2022. The new program is independent of the previous one, indicating a strengthened partnership and strategic alignment.
